|
REGULATORY
MATTERS
|
| • |
Atomoxetine
|
| • |
Buflomedil-containing
medicines |
| • |
Dasatinib |
| • |
Drotrecogin
alfa (activated) |
| • |
Drospirenone-containing
combined oral contraceptives |
| • |
Fenofibric
acid |
| • |
Fluoroquinolone |
| • |
Lenalidomide |
| • |
Modafinil |
| • |
Pioglitazone |
| • |
Rosiglitazone |
|
SAFETY
OF MEDICINE
|
| • |
Angiotensin
II receptor antagonists
|
| • |
Buccal
midazolam |
| • |
Citalopram |
| • |
Linezolid |
| • |
Methylene
Blue |
| • |
Pholcodine |
| • |
Tumor
Necrosis Factor (TNF) blockers, Azathioprine and/or Mercaptopurine |
|
FEATURE
|
| • |
A training
course on Cohort Event Monitoring of medicines used in HIV treatment
programmes
|
